MARKET

NTLA

NTLA

Intellia Therape
NASDAQ
30.84
+1.21
+4.08%
After Hours: 30.83 -0.01 -0.03% 19:38 12/01 EST
OPEN
29.57
PREV CLOSE
29.63
HIGH
30.85
LOW
28.46
VOLUME
1.54M
TURNOVER
0
52 WEEK HIGH
48.00
52 WEEK LOW
22.67
MARKET CAP
2.76B
P/E (TTM)
-5.7625
1D
5D
1M
3M
1Y
5Y
CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics
Intellia and crispr therapeutics are considered the top two players in the crispr space in the next 1 to 3 years. Ntla focuses on in vivo gene editing and has a comprehensive pipeline targeting genetic diseases and conditions. Crsp focuses on ex-vivo gene editing.
Seeking Alpha · 4d ago
Weekly Report: what happened at NTLA last week (1120-1124)?
Weekly Report · 6d ago
CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big
Gene editing allows scientists to modify the dna of organisms using biotechnological techniques. Crispr-cas9 is the most widely used gene editing technology. This 2-part series will cover the basics of gene editing and the major players involved in the field. I think it is an important time to learn about the technology.
Seeking Alpha · 11/25 08:39
Intellia Therapeutics files for mixed shelf
Intellia therapeutics files for mixed shelf offering without disclosing the amount. Intellia filed a prospectus for a mixed-shelf offering on friday. The company's stock is down 2% in the last three months; the nasdaq is up 2% this week.
Seeking Alpha · 11/24 16:31
Gene Editing Will Change Medicine -- and Maybe Health Investing Too -- Heard on the Street
First gene-editing treatment approved in the u.k. For sickle cell patients. Nobel prize-winning scientists have developed a tool to edit genes using crispr. Gene editing is part of a broader therapeutic revolution in genetic and cellular medicine. Wall street is excited about the field's long-term potential.
The Wall Street Journal · 11/24 12:00
Gene editing stocks slide after two-day rally
Gene editing stocks slide after two-day rally after two straight sessions of strong gains. Last week's rally followed the u.k. Approval of a crispr-based gene editing drug. Spdr s&p biotech etf has lost 2% on tuesday.
Seeking Alpha · 11/21 20:13
Monday's ETF Movers: ARKG, MOO
NASDAQ · 11/20 19:48
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Renew energy global plc shares rose 13.6% to $6.74 on monday. Renew energy posted quarterly sales of $345.00 million. Bruush oral care inc. Shares jumped 147.2% after reporting strong quarterly sales. Javier milei's victory in argentina's presidential election sparked a rally in argentine adrs.
Benzinga · 11/20 19:35
More
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). It is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned chimeric antigen receptor T (CAR-T) cell candidate, NTLA-6001 targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Hodgkin's lymphoma.

Webull offers Intellia Therapeutics Inc stock information, including NASDAQ: NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.